TriVascular, Inc

TriVascular, Inc. is a medical device company based in Santa Rosa, California, founded in 1998. The company focuses on developing less-invasive endovascular therapies for treating abdominal aortic aneurysms (AAA). Its flagship product, the Ovation Endovascular Stent Graft System, was launched in 2010. This innovative device features a unique design that incorporates an injectable polymer, allowing for delivery through a narrower catheter. This advancement enables treatment for a wider range of patients, including those with challenging vascular anatomies. TriVascular's technology offers a significant improvement over traditional open surgery for AAA repair, which is more invasive and requires a large abdominal incision. The endovascular approach reduces recovery time and procedural risks for patients. The company is also working on thoracic aortic stent-grafts to expand its treatment options for vascular diseases. In 2015, TriVascular was acquired by Boston Scientific, which has supported the further development and commercialization of its technologies.

• Employees 43
• Founded 1998
• Annual Revenue $35000000
• Total Funding $128000000